Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy

Bellarmine V. Lawrence, Allan Lipton, Harold Harvey, Richard J. Santen, Samuel A. Wells, Charles E. Cox, Deborah S. White, Emma K. Smart

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women. Estrogen receptor (ER) status in breast cancer is useful in predicting the response to the hormonal treatments. Of 134 postmenopausal metastatic breast cancer patients treated with AG, ER analysis was done in 63 patients, 52 of whom are now evaluable. ER biopsy was performed prior to AG therapy in 61 patients, but the results were not known to the investigators. Cancer 45:786‐791, 1980. ER value ⩽10 fmol/mg cytosol protein was considered ER positive (ER+), 4–9.9 fmol/mg borderline, and <4 fmol/mg ER negative (ER‐). In 38 ER+ patients, objective response rate was 50% (three complete response, 16 partial response) and eight stabilization. Median duration of objective response was 15 months. Forty‐three percent of the patients with borderline estrogen receptor level responded objectively (three partial response) with the median duration of response eleven months. Fourteen percent of ER– patients responded objectively (one complete response). Hence the estrogen receptor level predicts response in ER+ and ER borderline patients treated with AG. Cancer 45:786‐791, 1980.

Original languageEnglish (US)
Pages (from-to)786-791
Number of pages6
JournalCancer
Volume45
Issue number4
DOIs
StatePublished - Jan 1 1980

Fingerprint

Aminoglutethimide
Estrogen Receptors
Breast Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lawrence, Bellarmine V. ; Lipton, Allan ; Harvey, Harold ; Santen, Richard J. ; Wells, Samuel A. ; Cox, Charles E. ; White, Deborah S. ; Smart, Emma K. / Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. In: Cancer. 1980 ; Vol. 45, No. 4. pp. 786-791.
@article{b47fdec2491c4b13bb66cc0317efeac3,
title = "Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy",
abstract = "Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women. Estrogen receptor (ER) status in breast cancer is useful in predicting the response to the hormonal treatments. Of 134 postmenopausal metastatic breast cancer patients treated with AG, ER analysis was done in 63 patients, 52 of whom are now evaluable. ER biopsy was performed prior to AG therapy in 61 patients, but the results were not known to the investigators. Cancer 45:786‐791, 1980. ER value ⩽10 fmol/mg cytosol protein was considered ER positive (ER+), 4–9.9 fmol/mg borderline, and <4 fmol/mg ER negative (ER‐). In 38 ER+ patients, objective response rate was 50{\%} (three complete response, 16 partial response) and eight stabilization. Median duration of objective response was 15 months. Forty‐three percent of the patients with borderline estrogen receptor level responded objectively (three partial response) with the median duration of response eleven months. Fourteen percent of ER– patients responded objectively (one complete response). Hence the estrogen receptor level predicts response in ER+ and ER borderline patients treated with AG. Cancer 45:786‐791, 1980.",
author = "Lawrence, {Bellarmine V.} and Allan Lipton and Harold Harvey and Santen, {Richard J.} and Wells, {Samuel A.} and Cox, {Charles E.} and White, {Deborah S.} and Smart, {Emma K.}",
year = "1980",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19800215)45:4<786::AID-CNCR2820450429>3.0.CO;2-X",
language = "English (US)",
volume = "45",
pages = "786--791",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy. / Lawrence, Bellarmine V.; Lipton, Allan; Harvey, Harold; Santen, Richard J.; Wells, Samuel A.; Cox, Charles E.; White, Deborah S.; Smart, Emma K.

In: Cancer, Vol. 45, No. 4, 01.01.1980, p. 786-791.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Influence of estrogen receptor status on response of metastatic breast cancer to aminoglutethimide therapy

AU - Lawrence, Bellarmine V.

AU - Lipton, Allan

AU - Harvey, Harold

AU - Santen, Richard J.

AU - Wells, Samuel A.

AU - Cox, Charles E.

AU - White, Deborah S.

AU - Smart, Emma K.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women. Estrogen receptor (ER) status in breast cancer is useful in predicting the response to the hormonal treatments. Of 134 postmenopausal metastatic breast cancer patients treated with AG, ER analysis was done in 63 patients, 52 of whom are now evaluable. ER biopsy was performed prior to AG therapy in 61 patients, but the results were not known to the investigators. Cancer 45:786‐791, 1980. ER value ⩽10 fmol/mg cytosol protein was considered ER positive (ER+), 4–9.9 fmol/mg borderline, and <4 fmol/mg ER negative (ER‐). In 38 ER+ patients, objective response rate was 50% (three complete response, 16 partial response) and eight stabilization. Median duration of objective response was 15 months. Forty‐three percent of the patients with borderline estrogen receptor level responded objectively (three partial response) with the median duration of response eleven months. Fourteen percent of ER– patients responded objectively (one complete response). Hence the estrogen receptor level predicts response in ER+ and ER borderline patients treated with AG. Cancer 45:786‐791, 1980.

AB - Aminoglutethimide (AG) is an effective chemical ablative form of therapy for metastatic breast cancer in postmenopausal women. Estrogen receptor (ER) status in breast cancer is useful in predicting the response to the hormonal treatments. Of 134 postmenopausal metastatic breast cancer patients treated with AG, ER analysis was done in 63 patients, 52 of whom are now evaluable. ER biopsy was performed prior to AG therapy in 61 patients, but the results were not known to the investigators. Cancer 45:786‐791, 1980. ER value ⩽10 fmol/mg cytosol protein was considered ER positive (ER+), 4–9.9 fmol/mg borderline, and <4 fmol/mg ER negative (ER‐). In 38 ER+ patients, objective response rate was 50% (three complete response, 16 partial response) and eight stabilization. Median duration of objective response was 15 months. Forty‐three percent of the patients with borderline estrogen receptor level responded objectively (three partial response) with the median duration of response eleven months. Fourteen percent of ER– patients responded objectively (one complete response). Hence the estrogen receptor level predicts response in ER+ and ER borderline patients treated with AG. Cancer 45:786‐791, 1980.

UR - http://www.scopus.com/inward/record.url?scp=0018889113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018889113&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19800215)45:4<786::AID-CNCR2820450429>3.0.CO;2-X

DO - 10.1002/1097-0142(19800215)45:4<786::AID-CNCR2820450429>3.0.CO;2-X

M3 - Article

C2 - 7357495

AN - SCOPUS:0018889113

VL - 45

SP - 786

EP - 791

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -